Cargando…
Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflamm...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453937/ https://www.ncbi.nlm.nih.gov/pubmed/37626926 http://dx.doi.org/10.3390/cells12162115 |
_version_ | 1785096066674196480 |
---|---|
author | Saetzler, Valerie Riet, Tobias Schienke, Andrea Henschel, Pierre Freitag, Kiara Haake, Alexander Heppner, Frank L. Buitrago-Molina, Laura Elisa Noyan, Fatih Jaeckel, Elmar Hardtke-Wolenski, Matthias |
author_facet | Saetzler, Valerie Riet, Tobias Schienke, Andrea Henschel, Pierre Freitag, Kiara Haake, Alexander Heppner, Frank L. Buitrago-Molina, Laura Elisa Noyan, Fatih Jaeckel, Elmar Hardtke-Wolenski, Matthias |
author_sort | Saetzler, Valerie |
collection | PubMed |
description | Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging. Aims and Methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid. Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity. Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs. |
format | Online Article Text |
id | pubmed-10453937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104539372023-08-26 Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease Saetzler, Valerie Riet, Tobias Schienke, Andrea Henschel, Pierre Freitag, Kiara Haake, Alexander Heppner, Frank L. Buitrago-Molina, Laura Elisa Noyan, Fatih Jaeckel, Elmar Hardtke-Wolenski, Matthias Cells Article Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging. Aims and Methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid. Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity. Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs. MDPI 2023-08-21 /pmc/articles/PMC10453937/ /pubmed/37626926 http://dx.doi.org/10.3390/cells12162115 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Saetzler, Valerie Riet, Tobias Schienke, Andrea Henschel, Pierre Freitag, Kiara Haake, Alexander Heppner, Frank L. Buitrago-Molina, Laura Elisa Noyan, Fatih Jaeckel, Elmar Hardtke-Wolenski, Matthias Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease |
title | Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease |
title_full | Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease |
title_fullStr | Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease |
title_full_unstemmed | Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease |
title_short | Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease |
title_sort | development of beta-amyloid-specific car-tregs for the treatment of alzheimer’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453937/ https://www.ncbi.nlm.nih.gov/pubmed/37626926 http://dx.doi.org/10.3390/cells12162115 |
work_keys_str_mv | AT saetzlervalerie developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT riettobias developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT schienkeandrea developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT henschelpierre developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT freitagkiara developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT haakealexander developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT heppnerfrankl developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT buitragomolinalauraelisa developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT noyanfatih developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT jaeckelelmar developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease AT hardtkewolenskimatthias developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease |